Pearl Taylor M, Markert James M, Cassady Kevin A, Ghonime Mohammed G
The Ohio State University College of Medicine, Columbus, OH 43205, USA.
Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Mol Ther Oncolytics. 2019 Mar 20;13:14-21. doi: 10.1016/j.omto.2019.03.001. eCollection 2019 Jun 28.
Oncolytic viral therapy has gained significant traction as cancer therapy over the past 2 decades. Oncolytic viruses are uniquely designed both to lyse tumor cells through their replication and to recruit immune responses against virally infected cells. Increasingly, investigators are leveraging this immune response to target the immunosuppressive tumor microenvironment and improve immune effector response against bystander tumor cells. In this article, we review the spectrum of preclinical, early-stage clinical, and potential future efforts with cytokine-secreting oncolytic viruses, with a focus on the treatment of brain tumors and solid tumors.
在过去20年中，溶瘤病毒疗法作为一种癌症治疗方法已获得了显著的关注。溶瘤病毒经过独特设计，既能通过自身复制裂解肿瘤细胞，又能募集针对病毒感染细胞的免疫反应。越来越多的研究人员正在利用这种免疫反应来靶向免疫抑制性肿瘤微环境，并改善针对旁观者肿瘤细胞的免疫效应反应。在本文中，我们回顾了分泌细胞因子的溶瘤病毒在临床前、早期临床以及未来潜在研究方面的进展，重点关注脑肿瘤和实体瘤的治疗。
